Handelsavisen
prelaunch
Companies Healthcare 2581.HK
25
2581.HK HKEX Healthcare Facilities & Services

BenQ BM Holding Cayman Corp

HK$3,18
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

BenQ BM Holding Cayman Corp operates in the healthcare sector, focusing on pharmaceuticals and healthcare services.

Business. BenQ BM Holding Cayman Corp (2581.HK) is a healthcare company engaged in pharmaceutical activities within the Healthcare Facilities & Services industry. The firm operates on a service-revenue model and is headquartered in the Cayman Islands. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 2581.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 2581.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    BenQ BM Holding Cayman Corp (2581.HK) is a healthcare company engaged in pharmaceutical activities within the Healthcare Facilities & Services industry. The firm operates on a service-revenue model and is headquartered in the Cayman Islands. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    BenQ BM Holding Cayman Corp has a basic and diluted share count of 311,945,001, indicating no immediate dilution pressure from share issuance. However, the liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. This lack of financial transparency limits the ability to evaluate the company's short-term solvency and operational stability.

    The company's profitability and return metrics are not available in the current dataset, making it difficult to compare its performance against industry benchmarks or preferred metrics. Without access to key profitability indicators such as net margin, EBITDA, or ROIC, an assessment of its operational efficiency and capital returns is not feasible at this time.

    Segment and geographic exposure data are not disclosed in the available financial reports, which limits the ability to assess revenue concentration or diversification. This lack of segmental detail also prevents a granular understanding of the company's exposure to different markets or product lines.

    Growth trajectory data is not available in the current dataset, and no numeric deltas or revenue history are provided to evaluate the company's performance over time. This absence of historical data hinders the ability to project future growth or assess the company's market position.

    The risk assessment indicates a low level of dilution risk, but the liquidity risk remains unassessed. The absence of balance-sheet inputs and the lack of going-concern language in the source documents suggest a potential information gap that could affect the company's ability to meet short-term obligations. No dilution sources are explicitly identified in the available documents, and no adjustments are applied to the valuation metrics.

    Recent events, including filings and transcripts, are not disclosed in the available data, which limits the ability to assess the company's strategic direction or operational developments. The lack of recent disclosures may indicate limited public activity or a focus on private operations.

    Key takeaways
    • The company has no immediate dilution pressure, with basic and diluted shares outstanding being equal.
    • Liquidity risk cannot be assessed due to missing balance-sheet data and no going-concern language.
    • Profitability and return metrics are not available, limiting performance benchmarking.
    • Segment and geographic exposure details are not disclosed, making it difficult to assess diversification.
    • Growth trajectory and historical revenue data are not available for analysis.
    • Recent events and strategic developments are not disclosed in the available data.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    HK$3,18
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • BenQ BM Holding Cayman Corp Market data — financials · 2026-05-26

    Ownership & reference

    Leadership

    • Tze-Jung HsiaoChief Executive Officer, Executive Director

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    2581.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage